SLC5A2

Sodium/glucose cotransporter 2 · P31639 · SLC5A2 on Sugi Atlas →

54,251 patent compounds predicted against SLC5A2, 30,434 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL147718	1.00	20/20
SCHEMBL147932	1.00	20/20
SCHEMBL152222	1.00	20/20
SCHEMBL154633	1.00	20/20
SCHEMBL156012	1.00	20/20
Canagliflozin Anhydrous (SCHEMBL157162)	1.00	20/20
Dapagliflozin (SCHEMBL157820)	1.00	20/20
Dapagliflozin (SCHEMBL165603)	1.00	20/20
SCHEMBL207789	1.00	20/20
SCHEMBL220972	1.00	20/20
SCHEMBL254518	1.00	20/20
SCHEMBL301961	1.00	20/20
SCHEMBL302062	1.00	20/20
Bexagliflozin (SCHEMBL302200)	1.00	20/20
SCHEMBL303300	1.00	20/20
SCHEMBL303416	1.00	20/20
Canagliflozin Anhydrous (SCHEMBL322058)	1.00	20/20
Canagliflozin Anhydrous (SCHEMBL322059)	1.00	20/20
Canagliflozin Anhydrous (SCHEMBL322546)	1.00	20/20
Ipragliflozin (SCHEMBL337645)	1.00	20/20

Clinical trials — most relevant to SLC5A2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation.	PHASE4	COMPLETED
Metabolic Responses of Dapagliflozin vs Sitagliptin in T2DM Patients Inadequately Controlled With Insulin Therapy	PHASE4	COMPLETED
The Effects of Dapagliflozin on HDL Particles Subtypes and Reverse Cholesterol Transport in Type 2 Diabetic Patients	PHASE4	COMPLETED
Effect of Anti-diabetic Drugs on Glycemic Variability	PHASE4	COMPLETED
Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration	PHASE4	COMPLETED
Peri-treatment of SGLT-2 Inhibitor on Myocardial Infarct Size and Remodeling Index in Patients With Acute Myocardial Infarction and High Risk of Heart Failure Undergoing Percutaneous Coronary Intervention	PHASE4	RECRUITING
SGLT2 Inhibition in Combination With Diuretics in Heart Failure	PHASE4	COMPLETED
Effects of Sodium-glucose Co-transporter-2( SGLT-2 ) Inhibition on Sympathetic Nervous System Activity in Humans	PHASE4	UNKNOWN
Hepato-renal Regulation of Water Conservation in Heart Failure Patients With SGLT-2 Inhibitor Treatment	PHASE4	COMPLETED
Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction	PHASE3	COMPLETED
Empagliflozin in Hypertrophic Cardiomyopathy	PHASE3	ACTIVE_NOT_RECRUITING
Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients With Type 2 Diabetes	PHASE2	COMPLETED
Evaluating Safe Ketone Thresholds To Minimise Ketosis in People With Type 1 Diabetes Using Dapagliflozin	PHASE2	NOT_YET_RECRUITING
Dapagliflozin in Non-diabetic Stage IV CKD	PHASE2	COMPLETED
Analysing the Effect of Empagliflozin on Reduction of Tissue Sodium Content in Patients With Chronic Heart Failure	PHASE2	COMPLETED
Sotagliflozin in Patients With Heart Failure Symptoms and Type 1 Diabetes	PHASE2	RECRUITING
Empagliflozin in ESKD - A Feasibility Study	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients.	nan	RECRUITING
Sodium Glucose Co-Transporter 2 Inhibitors on Estimated Glomerular Filtration Rate in Diabetic Versus Non-Diabetic Chronic Kidney Disease Patients	nan	COMPLETED
Dapagliflozin in the Treatment of Heart Failure	nan	UNKNOWN
Impact of Sodium Glucose Co-transporter 2-Inhibitors on Clinical Outcome and Left Ventricular Function in Patients Presented by Acute Myocardial Infarction	nan	COMPLETED
Metabolic and Hemodynamic Effects of the Inhibitors of Type 2 Sodium Glucose Co-transporters (ISGLT2) in Diabetic Patients With Heart Failure	nan	COMPLETED
Comparative Effectiveness of Dapagliflozin Versus DPP-4 Inhibitors	nan	COMPLETED
The Effect of SGLT-2 Inhibitors on Epicardial Adipose Tissue and Cardiac Function in T2DM Patients With CAD (EpiCAD)	nan	UNKNOWN
SGLT-2 Inhibitors in the Treatment of Ascites	nan	ACTIVE_NOT_RECRUITING
Effect of Genetic Polymorphisms on the Clinical Response to SGLT2 Inhibitors in Heart Failure Patients	nan	UNKNOWN
Sodium-glucose Transporter Type 2 Inhibition in Anthracycline-related Cardiotoxicity	nan	RECRUITING
Using of SGLt2 Inhibitors in Patients With Type 2 DM	nan	UNKNOWN
Proteinuria in Renal Transplant Patients Treated With Dapagliflozin	nan	COMPLETED
Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors and Risk of Cardiovascular Events	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a SLC5A2 binder may also engage these)

Protein	Name	Similarity
Q2M3M2	—	1.000	Q2M3M2 →
SLC5A11	Sodium/myo-inositol cotransporter 2	0.999	landscape →
P53792	—	0.999	P53792 →
P26430	—	0.999	P26430 →
Q923I7	—	0.995	Q923I7 →
Q3ZC26	—	0.994	Q3ZC26 →
A8I1B9	—	0.990	A8I1B9 →
Q5SWY8	—	0.990	Q5SWY8 →
Q28728	—	0.990	Q28728 →
Q8VDT1	—	0.988	Q8VDT1 →
A0PJK1	—	0.988	A0PJK1 →
Q8K0E3	—	0.987	Q8K0E3 →
Q28610	—	0.986	Q28610 →
Q9Z1F2	—	0.985	Q9Z1F2 →
Q6R4Q5	—	0.984	Q6R4Q5 →
A8WHP3	—	0.983	A8WHP3 →
Q5FY69	—	0.981	Q5FY69 →
Q91ZP4	—	0.980	Q91ZP4 →
P53793	—	0.978	P53793 →
Q9ET37	—	0.977	Q9ET37 →
D3ZIS0	—	0.977	D3ZIS0 →
Q27981	—	0.976	Q27981 →
P49280	—	0.976	P49280 →
Q9NY91	—	0.975	Q9NY91 →
Q9XT74	—	0.974	Q9XT74 →
P53790	—	0.974	P53790 →
Q9JKZ2	—	0.974	Q9JKZ2 →
Q27946	—	0.974	Q27946 →
Q63008	—	0.973	Q63008 →
P31637	—	0.973	P31637 →